Global Oral Antibiotics Market

Oral Antibiotics Comprehensive Study by Type (Branded, Generic), Application (Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI)), Urinary Acquired Tract Infections (UTIS), Dental (Combination, and Monotherapies), Others), Spectrum of Activity (Broad-Spectrum Antibiotic, Narrow-Spectrum Antibiotic), Drug Origin (Natural, Semisynthetic, Synthetic), Class (Beta-Lactam and Beta-Lactamase Inhibitors, Quinolone, Macrolide, Others) Players and Region - Global Market Outlook to 2028

Oral Antibiotics Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Oral Antibiotics Market Scope?
Antibiotic is an antimicrobial substance or a compound that fights against bacterial infections and sometimes with protozoan infections, but not viral infections. These are medications that either stop bacteria from growing or kill bacteria directly, referred to as bacteriostatic and bactericidal antibiotics, respectively. An increase in the incidence of chronic and infectious diseases across the globe and the efficacy of antibiotics to treat a wide spectrum of bacterial infections has led to the rapid growth of the global oral antibiotics market.

Influencing Trend:
Development of Novel Approaches for new Antibiotics to Treat Bacterial Infections

Market Growth Drivers:
Rising in Prevalence of Infectious Diseases across the Globe and Increase in Demand for Antibiotics, owing to Increased Consumption in Low- and Middle-Income Countries

Challenges:
Presence of Several Antibiotics

Restraints:
Several Side Effect Occurs due to high Consumption of the Antibiotics

Opportunities:
Novel Combination Therapies to Treat Antibiotic-Resistant Microbial Infections

The Oral Antibiotics market study is being classified by Type (Branded and Generic), by Application and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Oral Antibiotics market throughout the predicted period.

Abbott Laboratories (United States), Allergan Plc. (Ireland), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc (United Kingdom), Merck & Co. Inc. (United States), Mylan N.V. (United States), Novartis International AG (Sandoz), Pfizer Inc. (United States), Sanofi (France) and Teva Pharmaceutical Industries Ltd. (Israel) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Oral Antibiotics market by Type, Application and Region.

On the basis of geography, the market of Oral Antibiotics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In January 2018, Melinta Therapeutics, Inc launched Baxdela (delafloxacin), an oral fluoroquinolone for the treatment of acute bacterial skin and skin structure infections (ABSSSI) which is caused by designated susceptible bacteria. The launch of Baxdela provides new treatment options as well as expands the company’s portfolio in the infection therapeutics area.


Key Target Audience
Oral Antibiotics Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Oral Antibiotics Market Study: Important Years
AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Major Highlights of Market Study

Demand Determinants: Identifying top-notch application and business segments that seek high growth potentials in Oral Antibiotics Market.

Key Strategic Developments: To target untapped regions more aggressively by focusing on product/service developments, innovation and R & D, new launches, Merger & acquisitions, JVs & partnerships.

Forces & Market Dynamics: Growth drivers, restraints & opportunities available in Oral Antibiotics industry is examined with reference relevant market sectors and sub-sectors.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also includes significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets, To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Branded
  • Generic
By Application
  • Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI))
  • Urinary Acquired Tract Infections (UTIS)
  • Dental (Combination, and Monotherapies)
  • Others
By Spectrum of Activity
  • Broad-Spectrum Antibiotic
  • Narrow-Spectrum Antibiotic

By Drug Origin
  • Natural
  • Semisynthetic
  • Synthetic

By Class
  • Beta-Lactam and Beta-Lactamase Inhibitors
  • Quinolone
  • Macrolide
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising in Prevalence of Infectious Diseases across the Globe
      • 3.2.2. Increase in Demand for Antibiotics, owing to Increased Consumption in Low- and Middle-Income Countries
    • 3.3. Market Challenges
      • 3.3.1. Presence of Several Antibiotics
    • 3.4. Market Trends
      • 3.4.1. Development of Novel Approaches for new Antibiotics to Treat Bacterial Infections
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oral Antibiotics, by Type, Application, Spectrum of Activity, Drug Origin, Class and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Oral Antibiotics (Value)
      • 5.2.1. Global Oral Antibiotics by: Type (Value)
        • 5.2.1.1. Branded
        • 5.2.1.2. Generic
      • 5.2.2. Global Oral Antibiotics by: Application (Value)
        • 5.2.2.1. Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI))
        • 5.2.2.2. Urinary Acquired Tract Infections (UTIS)
        • 5.2.2.3. Dental (Combination, and Monotherapies)
        • 5.2.2.4. Others
      • 5.2.3. Global Oral Antibiotics by: Spectrum of Activity (Value)
        • 5.2.3.1. Broad-Spectrum Antibiotic
        • 5.2.3.2. Narrow-Spectrum Antibiotic
      • 5.2.4. Global Oral Antibiotics by: Drug Origin (Value)
        • 5.2.4.1. Natural
        • 5.2.4.2. Semisynthetic
        • 5.2.4.3. Synthetic
      • 5.2.5. Global Oral Antibiotics by: Class (Value)
        • 5.2.5.1. Beta-Lactam and Beta-Lactamase Inhibitors
        • 5.2.5.2. Quinolone
        • 5.2.5.3. Macrolide
        • 5.2.5.4. Others
      • 5.2.6. Global Oral Antibiotics Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Oral Antibiotics (Volume)
      • 5.3.1. Global Oral Antibiotics by: Type (Volume)
        • 5.3.1.1. Branded
        • 5.3.1.2. Generic
      • 5.3.2. Global Oral Antibiotics by: Application (Volume)
        • 5.3.2.1. Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI))
        • 5.3.2.2. Urinary Acquired Tract Infections (UTIS)
        • 5.3.2.3. Dental (Combination, and Monotherapies)
        • 5.3.2.4. Others
      • 5.3.3. Global Oral Antibiotics by: Spectrum of Activity (Volume)
        • 5.3.3.1. Broad-Spectrum Antibiotic
        • 5.3.3.2. Narrow-Spectrum Antibiotic
      • 5.3.4. Global Oral Antibiotics by: Drug Origin (Volume)
        • 5.3.4.1. Natural
        • 5.3.4.2. Semisynthetic
        • 5.3.4.3. Synthetic
      • 5.3.5. Global Oral Antibiotics by: Class (Volume)
        • 5.3.5.1. Beta-Lactam and Beta-Lactamase Inhibitors
        • 5.3.5.2. Quinolone
        • 5.3.5.3. Macrolide
        • 5.3.5.4. Others
      • 5.3.6. Global Oral Antibiotics Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Oral Antibiotics (Price)
      • 5.4.1. Global Oral Antibiotics by: Type (Price)
  • 6. Oral Antibiotics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Allergan Plc. (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co. Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mylan N.V. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis International AG (Sandoz)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Oral Antibiotics Sale, by Type, Application, Spectrum of Activity, Drug Origin, Class and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Oral Antibiotics (Value)
      • 7.2.1. Global Oral Antibiotics by: Type (Value)
        • 7.2.1.1. Branded
        • 7.2.1.2. Generic
      • 7.2.2. Global Oral Antibiotics by: Application (Value)
        • 7.2.2.1. Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI))
        • 7.2.2.2. Urinary Acquired Tract Infections (UTIS)
        • 7.2.2.3. Dental (Combination, and Monotherapies)
        • 7.2.2.4. Others
      • 7.2.3. Global Oral Antibiotics by: Spectrum of Activity (Value)
        • 7.2.3.1. Broad-Spectrum Antibiotic
        • 7.2.3.2. Narrow-Spectrum Antibiotic
      • 7.2.4. Global Oral Antibiotics by: Drug Origin (Value)
        • 7.2.4.1. Natural
        • 7.2.4.2. Semisynthetic
        • 7.2.4.3. Synthetic
      • 7.2.5. Global Oral Antibiotics by: Class (Value)
        • 7.2.5.1. Beta-Lactam and Beta-Lactamase Inhibitors
        • 7.2.5.2. Quinolone
        • 7.2.5.3. Macrolide
        • 7.2.5.4. Others
      • 7.2.6. Global Oral Antibiotics Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Oral Antibiotics (Volume)
      • 7.3.1. Global Oral Antibiotics by: Type (Volume)
        • 7.3.1.1. Branded
        • 7.3.1.2. Generic
      • 7.3.2. Global Oral Antibiotics by: Application (Volume)
        • 7.3.2.1. Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI))
        • 7.3.2.2. Urinary Acquired Tract Infections (UTIS)
        • 7.3.2.3. Dental (Combination, and Monotherapies)
        • 7.3.2.4. Others
      • 7.3.3. Global Oral Antibiotics by: Spectrum of Activity (Volume)
        • 7.3.3.1. Broad-Spectrum Antibiotic
        • 7.3.3.2. Narrow-Spectrum Antibiotic
      • 7.3.4. Global Oral Antibiotics by: Drug Origin (Volume)
        • 7.3.4.1. Natural
        • 7.3.4.2. Semisynthetic
        • 7.3.4.3. Synthetic
      • 7.3.5. Global Oral Antibiotics by: Class (Volume)
        • 7.3.5.1. Beta-Lactam and Beta-Lactamase Inhibitors
        • 7.3.5.2. Quinolone
        • 7.3.5.3. Macrolide
        • 7.3.5.4. Others
      • 7.3.6. Global Oral Antibiotics Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Oral Antibiotics (Price)
      • 7.4.1. Global Oral Antibiotics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oral Antibiotics: by Type(USD Million)
  • Table 2. Oral Antibiotics Branded , by Region USD Million (2017-2022)
  • Table 3. Oral Antibiotics Generic , by Region USD Million (2017-2022)
  • Table 4. Oral Antibiotics: by Application(USD Million)
  • Table 5. Oral Antibiotics Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI)) , by Region USD Million (2017-2022)
  • Table 6. Oral Antibiotics Urinary Acquired Tract Infections (UTIS) , by Region USD Million (2017-2022)
  • Table 7. Oral Antibiotics Dental (Combination, and Monotherapies) , by Region USD Million (2017-2022)
  • Table 8. Oral Antibiotics Others , by Region USD Million (2017-2022)
  • Table 9. Oral Antibiotics: by Spectrum of Activity(USD Million)
  • Table 10. Oral Antibiotics Broad-Spectrum Antibiotic , by Region USD Million (2017-2022)
  • Table 11. Oral Antibiotics Narrow-Spectrum Antibiotic , by Region USD Million (2017-2022)
  • Table 12. Oral Antibiotics: by Drug Origin(USD Million)
  • Table 13. Oral Antibiotics Natural , by Region USD Million (2017-2022)
  • Table 14. Oral Antibiotics Semisynthetic , by Region USD Million (2017-2022)
  • Table 15. Oral Antibiotics Synthetic , by Region USD Million (2017-2022)
  • Table 16. Oral Antibiotics: by Class(USD Million)
  • Table 17. Oral Antibiotics Beta-Lactam and Beta-Lactamase Inhibitors , by Region USD Million (2017-2022)
  • Table 18. Oral Antibiotics Quinolone , by Region USD Million (2017-2022)
  • Table 19. Oral Antibiotics Macrolide , by Region USD Million (2017-2022)
  • Table 20. Oral Antibiotics Others , by Region USD Million (2017-2022)
  • Table 21. South America Oral Antibiotics, by Country USD Million (2017-2022)
  • Table 22. South America Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 23. South America Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 24. South America Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 25. South America Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 26. South America Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 27. Brazil Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 28. Brazil Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 29. Brazil Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 30. Brazil Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 31. Brazil Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 32. Argentina Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 33. Argentina Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 34. Argentina Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 35. Argentina Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 36. Argentina Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 37. Rest of South America Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 38. Rest of South America Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 39. Rest of South America Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 40. Rest of South America Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 41. Rest of South America Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 42. Asia Pacific Oral Antibiotics, by Country USD Million (2017-2022)
  • Table 43. Asia Pacific Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 44. Asia Pacific Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 45. Asia Pacific Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 46. Asia Pacific Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 47. Asia Pacific Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 48. China Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 49. China Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 50. China Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 51. China Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 52. China Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 53. Japan Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 54. Japan Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 55. Japan Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 56. Japan Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 57. Japan Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 58. India Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 59. India Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 60. India Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 61. India Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 62. India Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 63. South Korea Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 64. South Korea Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 65. South Korea Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 66. South Korea Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 67. South Korea Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 68. Taiwan Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 69. Taiwan Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 70. Taiwan Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 71. Taiwan Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 72. Taiwan Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 73. Australia Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 74. Australia Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 75. Australia Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 76. Australia Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 77. Australia Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 78. Rest of Asia-Pacific Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 79. Rest of Asia-Pacific Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 80. Rest of Asia-Pacific Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 81. Rest of Asia-Pacific Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 82. Rest of Asia-Pacific Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 83. Europe Oral Antibiotics, by Country USD Million (2017-2022)
  • Table 84. Europe Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 85. Europe Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 86. Europe Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 87. Europe Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 88. Europe Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 89. Germany Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 90. Germany Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 91. Germany Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 92. Germany Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 93. Germany Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 94. France Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 95. France Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 96. France Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 97. France Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 98. France Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 99. Italy Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 100. Italy Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 101. Italy Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 102. Italy Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 103. Italy Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 104. United Kingdom Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 105. United Kingdom Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 106. United Kingdom Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 107. United Kingdom Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 108. United Kingdom Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 109. Netherlands Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 110. Netherlands Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 111. Netherlands Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 112. Netherlands Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 113. Netherlands Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 114. Rest of Europe Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 115. Rest of Europe Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 116. Rest of Europe Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 117. Rest of Europe Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 118. Rest of Europe Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 119. MEA Oral Antibiotics, by Country USD Million (2017-2022)
  • Table 120. MEA Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 121. MEA Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 122. MEA Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 123. MEA Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 124. MEA Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 125. Middle East Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 126. Middle East Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 127. Middle East Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 128. Middle East Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 129. Middle East Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 130. Africa Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 131. Africa Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 132. Africa Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 133. Africa Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 134. Africa Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 135. North America Oral Antibiotics, by Country USD Million (2017-2022)
  • Table 136. North America Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 137. North America Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 138. North America Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 139. North America Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 140. North America Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 141. United States Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 142. United States Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 143. United States Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 144. United States Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 145. United States Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 146. Canada Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 147. Canada Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 148. Canada Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 149. Canada Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 150. Canada Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 151. Mexico Oral Antibiotics, by Type USD Million (2017-2022)
  • Table 152. Mexico Oral Antibiotics, by Application USD Million (2017-2022)
  • Table 153. Mexico Oral Antibiotics, by Spectrum of Activity USD Million (2017-2022)
  • Table 154. Mexico Oral Antibiotics, by Drug Origin USD Million (2017-2022)
  • Table 155. Mexico Oral Antibiotics, by Class USD Million (2017-2022)
  • Table 156. Oral Antibiotics Sales: by Type(KG)
  • Table 157. Oral Antibiotics Sales Branded , by Region KG (2017-2022)
  • Table 158. Oral Antibiotics Sales Generic , by Region KG (2017-2022)
  • Table 159. Oral Antibiotics Sales: by Application(KG)
  • Table 160. Oral Antibiotics Sales Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI)) , by Region KG (2017-2022)
  • Table 161. Oral Antibiotics Sales Urinary Acquired Tract Infections (UTIS) , by Region KG (2017-2022)
  • Table 162. Oral Antibiotics Sales Dental (Combination, and Monotherapies) , by Region KG (2017-2022)
  • Table 163. Oral Antibiotics Sales Others , by Region KG (2017-2022)
  • Table 164. Oral Antibiotics Sales: by Spectrum of Activity(KG)
  • Table 165. Oral Antibiotics Sales Broad-Spectrum Antibiotic , by Region KG (2017-2022)
  • Table 166. Oral Antibiotics Sales Narrow-Spectrum Antibiotic , by Region KG (2017-2022)
  • Table 167. Oral Antibiotics Sales: by Drug Origin(KG)
  • Table 168. Oral Antibiotics Sales Natural , by Region KG (2017-2022)
  • Table 169. Oral Antibiotics Sales Semisynthetic , by Region KG (2017-2022)
  • Table 170. Oral Antibiotics Sales Synthetic , by Region KG (2017-2022)
  • Table 171. Oral Antibiotics Sales: by Class(KG)
  • Table 172. Oral Antibiotics Sales Beta-Lactam and Beta-Lactamase Inhibitors , by Region KG (2017-2022)
  • Table 173. Oral Antibiotics Sales Quinolone , by Region KG (2017-2022)
  • Table 174. Oral Antibiotics Sales Macrolide , by Region KG (2017-2022)
  • Table 175. Oral Antibiotics Sales Others , by Region KG (2017-2022)
  • Table 176. South America Oral Antibiotics Sales, by Country KG (2017-2022)
  • Table 177. South America Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 178. South America Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 179. South America Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 180. South America Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 181. South America Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 182. Brazil Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 183. Brazil Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 184. Brazil Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 185. Brazil Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 186. Brazil Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 187. Argentina Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 188. Argentina Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 189. Argentina Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 190. Argentina Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 191. Argentina Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 192. Rest of South America Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 193. Rest of South America Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 194. Rest of South America Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 195. Rest of South America Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 196. Rest of South America Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 197. Asia Pacific Oral Antibiotics Sales, by Country KG (2017-2022)
  • Table 198. Asia Pacific Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 199. Asia Pacific Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 200. Asia Pacific Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 201. Asia Pacific Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 202. Asia Pacific Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 203. China Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 204. China Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 205. China Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 206. China Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 207. China Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 208. Japan Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 209. Japan Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 210. Japan Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 211. Japan Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 212. Japan Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 213. India Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 214. India Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 215. India Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 216. India Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 217. India Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 218. South Korea Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 219. South Korea Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 220. South Korea Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 221. South Korea Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 222. South Korea Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 223. Taiwan Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 224. Taiwan Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 225. Taiwan Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 226. Taiwan Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 227. Taiwan Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 228. Australia Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 229. Australia Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 230. Australia Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 231. Australia Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 232. Australia Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 233. Rest of Asia-Pacific Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 234. Rest of Asia-Pacific Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 235. Rest of Asia-Pacific Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 236. Rest of Asia-Pacific Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 237. Rest of Asia-Pacific Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 238. Europe Oral Antibiotics Sales, by Country KG (2017-2022)
  • Table 239. Europe Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 240. Europe Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 241. Europe Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 242. Europe Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 243. Europe Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 244. Germany Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 245. Germany Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 246. Germany Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 247. Germany Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 248. Germany Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 249. France Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 250. France Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 251. France Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 252. France Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 253. France Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 254. Italy Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 255. Italy Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 256. Italy Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 257. Italy Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 258. Italy Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 259. United Kingdom Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 260. United Kingdom Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 261. United Kingdom Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 262. United Kingdom Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 263. United Kingdom Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 264. Netherlands Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 265. Netherlands Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 266. Netherlands Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 267. Netherlands Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 268. Netherlands Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 269. Rest of Europe Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 270. Rest of Europe Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 271. Rest of Europe Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 272. Rest of Europe Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 273. Rest of Europe Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 274. MEA Oral Antibiotics Sales, by Country KG (2017-2022)
  • Table 275. MEA Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 276. MEA Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 277. MEA Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 278. MEA Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 279. MEA Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 280. Middle East Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 281. Middle East Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 282. Middle East Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 283. Middle East Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 284. Middle East Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 285. Africa Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 286. Africa Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 287. Africa Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 288. Africa Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 289. Africa Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 290. North America Oral Antibiotics Sales, by Country KG (2017-2022)
  • Table 291. North America Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 292. North America Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 293. North America Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 294. North America Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 295. North America Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 296. United States Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 297. United States Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 298. United States Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 299. United States Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 300. United States Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 301. Canada Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 302. Canada Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 303. Canada Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 304. Canada Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 305. Canada Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 306. Mexico Oral Antibiotics Sales, by Type KG (2017-2022)
  • Table 307. Mexico Oral Antibiotics Sales, by Application KG (2017-2022)
  • Table 308. Mexico Oral Antibiotics Sales, by Spectrum of Activity KG (2017-2022)
  • Table 309. Mexico Oral Antibiotics Sales, by Drug Origin KG (2017-2022)
  • Table 310. Mexico Oral Antibiotics Sales, by Class KG (2017-2022)
  • Table 311. Oral Antibiotics: by Type(USD/Units)
  • Table 312. Company Basic Information, Sales Area and Its Competitors
  • Table 313. Company Basic Information, Sales Area and Its Competitors
  • Table 314. Company Basic Information, Sales Area and Its Competitors
  • Table 315. Company Basic Information, Sales Area and Its Competitors
  • Table 316. Company Basic Information, Sales Area and Its Competitors
  • Table 317. Company Basic Information, Sales Area and Its Competitors
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Oral Antibiotics: by Type(USD Million)
  • Table 323. Oral Antibiotics Branded , by Region USD Million (2023-2028)
  • Table 324. Oral Antibiotics Generic , by Region USD Million (2023-2028)
  • Table 325. Oral Antibiotics: by Application(USD Million)
  • Table 326. Oral Antibiotics Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI)) , by Region USD Million (2023-2028)
  • Table 327. Oral Antibiotics Urinary Acquired Tract Infections (UTIS) , by Region USD Million (2023-2028)
  • Table 328. Oral Antibiotics Dental (Combination, and Monotherapies) , by Region USD Million (2023-2028)
  • Table 329. Oral Antibiotics Others , by Region USD Million (2023-2028)
  • Table 330. Oral Antibiotics: by Spectrum of Activity(USD Million)
  • Table 331. Oral Antibiotics Broad-Spectrum Antibiotic , by Region USD Million (2023-2028)
  • Table 332. Oral Antibiotics Narrow-Spectrum Antibiotic , by Region USD Million (2023-2028)
  • Table 333. Oral Antibiotics: by Drug Origin(USD Million)
  • Table 334. Oral Antibiotics Natural , by Region USD Million (2023-2028)
  • Table 335. Oral Antibiotics Semisynthetic , by Region USD Million (2023-2028)
  • Table 336. Oral Antibiotics Synthetic , by Region USD Million (2023-2028)
  • Table 337. Oral Antibiotics: by Class(USD Million)
  • Table 338. Oral Antibiotics Beta-Lactam and Beta-Lactamase Inhibitors , by Region USD Million (2023-2028)
  • Table 339. Oral Antibiotics Quinolone , by Region USD Million (2023-2028)
  • Table 340. Oral Antibiotics Macrolide , by Region USD Million (2023-2028)
  • Table 341. Oral Antibiotics Others , by Region USD Million (2023-2028)
  • Table 342. South America Oral Antibiotics, by Country USD Million (2023-2028)
  • Table 343. South America Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 344. South America Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 345. South America Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 346. South America Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 347. South America Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 348. Brazil Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 349. Brazil Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 350. Brazil Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 351. Brazil Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 352. Brazil Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 353. Argentina Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 354. Argentina Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 355. Argentina Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 356. Argentina Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 357. Argentina Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 358. Rest of South America Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 359. Rest of South America Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 360. Rest of South America Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 361. Rest of South America Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 362. Rest of South America Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 363. Asia Pacific Oral Antibiotics, by Country USD Million (2023-2028)
  • Table 364. Asia Pacific Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 365. Asia Pacific Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 366. Asia Pacific Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 367. Asia Pacific Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 368. Asia Pacific Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 369. China Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 370. China Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 371. China Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 372. China Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 373. China Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 374. Japan Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 375. Japan Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 376. Japan Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 377. Japan Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 378. Japan Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 379. India Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 380. India Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 381. India Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 382. India Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 383. India Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 384. South Korea Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 385. South Korea Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 386. South Korea Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 387. South Korea Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 388. South Korea Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 389. Taiwan Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 390. Taiwan Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 391. Taiwan Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 392. Taiwan Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 393. Taiwan Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 394. Australia Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 395. Australia Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 396. Australia Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 397. Australia Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 398. Australia Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 399. Rest of Asia-Pacific Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 400. Rest of Asia-Pacific Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 401. Rest of Asia-Pacific Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 402. Rest of Asia-Pacific Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 403. Rest of Asia-Pacific Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 404. Europe Oral Antibiotics, by Country USD Million (2023-2028)
  • Table 405. Europe Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 406. Europe Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 407. Europe Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 408. Europe Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 409. Europe Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 410. Germany Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 411. Germany Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 412. Germany Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 413. Germany Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 414. Germany Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 415. France Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 416. France Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 417. France Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 418. France Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 419. France Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 420. Italy Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 421. Italy Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 422. Italy Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 423. Italy Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 424. Italy Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 425. United Kingdom Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 426. United Kingdom Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 427. United Kingdom Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 428. United Kingdom Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 429. United Kingdom Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 430. Netherlands Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 431. Netherlands Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 432. Netherlands Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 433. Netherlands Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 434. Netherlands Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 435. Rest of Europe Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 436. Rest of Europe Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 437. Rest of Europe Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 438. Rest of Europe Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 439. Rest of Europe Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 440. MEA Oral Antibiotics, by Country USD Million (2023-2028)
  • Table 441. MEA Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 442. MEA Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 443. MEA Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 444. MEA Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 445. MEA Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 446. Middle East Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 447. Middle East Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 448. Middle East Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 449. Middle East Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 450. Middle East Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 451. Africa Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 452. Africa Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 453. Africa Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 454. Africa Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 455. Africa Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 456. North America Oral Antibiotics, by Country USD Million (2023-2028)
  • Table 457. North America Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 458. North America Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 459. North America Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 460. North America Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 461. North America Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 462. United States Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 463. United States Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 464. United States Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 465. United States Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 466. United States Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 467. Canada Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 468. Canada Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 469. Canada Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 470. Canada Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 471. Canada Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 472. Mexico Oral Antibiotics, by Type USD Million (2023-2028)
  • Table 473. Mexico Oral Antibiotics, by Application USD Million (2023-2028)
  • Table 474. Mexico Oral Antibiotics, by Spectrum of Activity USD Million (2023-2028)
  • Table 475. Mexico Oral Antibiotics, by Drug Origin USD Million (2023-2028)
  • Table 476. Mexico Oral Antibiotics, by Class USD Million (2023-2028)
  • Table 477. Oral Antibiotics Sales: by Type(KG)
  • Table 478. Oral Antibiotics Sales Branded , by Region KG (2023-2028)
  • Table 479. Oral Antibiotics Sales Generic , by Region KG (2023-2028)
  • Table 480. Oral Antibiotics Sales: by Application(KG)
  • Table 481. Oral Antibiotics Sales Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI)) , by Region KG (2023-2028)
  • Table 482. Oral Antibiotics Sales Urinary Acquired Tract Infections (UTIS) , by Region KG (2023-2028)
  • Table 483. Oral Antibiotics Sales Dental (Combination, and Monotherapies) , by Region KG (2023-2028)
  • Table 484. Oral Antibiotics Sales Others , by Region KG (2023-2028)
  • Table 485. Oral Antibiotics Sales: by Spectrum of Activity(KG)
  • Table 486. Oral Antibiotics Sales Broad-Spectrum Antibiotic , by Region KG (2023-2028)
  • Table 487. Oral Antibiotics Sales Narrow-Spectrum Antibiotic , by Region KG (2023-2028)
  • Table 488. Oral Antibiotics Sales: by Drug Origin(KG)
  • Table 489. Oral Antibiotics Sales Natural , by Region KG (2023-2028)
  • Table 490. Oral Antibiotics Sales Semisynthetic , by Region KG (2023-2028)
  • Table 491. Oral Antibiotics Sales Synthetic , by Region KG (2023-2028)
  • Table 492. Oral Antibiotics Sales: by Class(KG)
  • Table 493. Oral Antibiotics Sales Beta-Lactam and Beta-Lactamase Inhibitors , by Region KG (2023-2028)
  • Table 494. Oral Antibiotics Sales Quinolone , by Region KG (2023-2028)
  • Table 495. Oral Antibiotics Sales Macrolide , by Region KG (2023-2028)
  • Table 496. Oral Antibiotics Sales Others , by Region KG (2023-2028)
  • Table 497. South America Oral Antibiotics Sales, by Country KG (2023-2028)
  • Table 498. South America Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 499. South America Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 500. South America Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 501. South America Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 502. South America Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 503. Brazil Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 504. Brazil Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 505. Brazil Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 506. Brazil Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 507. Brazil Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 508. Argentina Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 509. Argentina Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 510. Argentina Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 511. Argentina Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 512. Argentina Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 513. Rest of South America Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 514. Rest of South America Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 515. Rest of South America Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 516. Rest of South America Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 517. Rest of South America Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 518. Asia Pacific Oral Antibiotics Sales, by Country KG (2023-2028)
  • Table 519. Asia Pacific Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 520. Asia Pacific Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 521. Asia Pacific Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 522. Asia Pacific Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 523. Asia Pacific Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 524. China Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 525. China Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 526. China Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 527. China Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 528. China Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 529. Japan Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 530. Japan Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 531. Japan Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 532. Japan Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 533. Japan Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 534. India Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 535. India Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 536. India Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 537. India Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 538. India Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 539. South Korea Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 540. South Korea Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 541. South Korea Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 542. South Korea Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 543. South Korea Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 544. Taiwan Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 545. Taiwan Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 546. Taiwan Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 547. Taiwan Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 548. Taiwan Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 549. Australia Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 550. Australia Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 551. Australia Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 552. Australia Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 553. Australia Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 554. Rest of Asia-Pacific Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 555. Rest of Asia-Pacific Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 556. Rest of Asia-Pacific Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 557. Rest of Asia-Pacific Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 558. Rest of Asia-Pacific Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 559. Europe Oral Antibiotics Sales, by Country KG (2023-2028)
  • Table 560. Europe Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 561. Europe Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 562. Europe Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 563. Europe Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 564. Europe Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 565. Germany Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 566. Germany Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 567. Germany Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 568. Germany Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 569. Germany Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 570. France Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 571. France Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 572. France Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 573. France Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 574. France Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 575. Italy Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 576. Italy Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 577. Italy Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 578. Italy Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 579. Italy Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 580. United Kingdom Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 581. United Kingdom Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 582. United Kingdom Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 583. United Kingdom Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 584. United Kingdom Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 585. Netherlands Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 586. Netherlands Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 587. Netherlands Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 588. Netherlands Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 589. Netherlands Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 590. Rest of Europe Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 591. Rest of Europe Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 592. Rest of Europe Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 593. Rest of Europe Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 594. Rest of Europe Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 595. MEA Oral Antibiotics Sales, by Country KG (2023-2028)
  • Table 596. MEA Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 597. MEA Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 598. MEA Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 599. MEA Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 600. MEA Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 601. Middle East Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 602. Middle East Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 603. Middle East Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 604. Middle East Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 605. Middle East Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 606. Africa Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 607. Africa Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 608. Africa Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 609. Africa Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 610. Africa Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 611. North America Oral Antibiotics Sales, by Country KG (2023-2028)
  • Table 612. North America Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 613. North America Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 614. North America Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 615. North America Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 616. North America Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 617. United States Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 618. United States Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 619. United States Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 620. United States Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 621. United States Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 622. Canada Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 623. Canada Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 624. Canada Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 625. Canada Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 626. Canada Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 627. Mexico Oral Antibiotics Sales, by Type KG (2023-2028)
  • Table 628. Mexico Oral Antibiotics Sales, by Application KG (2023-2028)
  • Table 629. Mexico Oral Antibiotics Sales, by Spectrum of Activity KG (2023-2028)
  • Table 630. Mexico Oral Antibiotics Sales, by Drug Origin KG (2023-2028)
  • Table 631. Mexico Oral Antibiotics Sales, by Class KG (2023-2028)
  • Table 632. Oral Antibiotics: by Type(USD/Units)
  • Table 633. Research Programs/Design for This Report
  • Table 634. Key Data Information from Secondary Sources
  • Table 635. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oral Antibiotics: by Type USD Million (2017-2022)
  • Figure 5. Global Oral Antibiotics: by Application USD Million (2017-2022)
  • Figure 6. Global Oral Antibiotics: by Spectrum of Activity USD Million (2017-2022)
  • Figure 7. Global Oral Antibiotics: by Drug Origin USD Million (2017-2022)
  • Figure 8. Global Oral Antibiotics: by Class USD Million (2017-2022)
  • Figure 9. South America Oral Antibiotics Share (%), by Country
  • Figure 10. Asia Pacific Oral Antibiotics Share (%), by Country
  • Figure 11. Europe Oral Antibiotics Share (%), by Country
  • Figure 12. MEA Oral Antibiotics Share (%), by Country
  • Figure 13. North America Oral Antibiotics Share (%), by Country
  • Figure 14. Global Oral Antibiotics: by Type KG (2017-2022)
  • Figure 15. Global Oral Antibiotics: by Application KG (2017-2022)
  • Figure 16. Global Oral Antibiotics: by Spectrum of Activity KG (2017-2022)
  • Figure 17. Global Oral Antibiotics: by Drug Origin KG (2017-2022)
  • Figure 18. Global Oral Antibiotics: by Class KG (2017-2022)
  • Figure 19. South America Oral Antibiotics Share (%), by Country
  • Figure 20. Asia Pacific Oral Antibiotics Share (%), by Country
  • Figure 21. Europe Oral Antibiotics Share (%), by Country
  • Figure 22. MEA Oral Antibiotics Share (%), by Country
  • Figure 23. North America Oral Antibiotics Share (%), by Country
  • Figure 24. Global Oral Antibiotics: by Type USD/Units (2017-2022)
  • Figure 25. Global Oral Antibiotics share by Players 2022 (%)
  • Figure 26. Global Oral Antibiotics share by Players (Top 3) 2022(%)
  • Figure 27. Global Oral Antibiotics share by Players (Top 5) 2022(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 30. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 31. Allergan Plc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 32. Allergan Plc. (Ireland) Revenue: by Geography 2022
  • Figure 33. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2022
  • Figure 35. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 37. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Merck & Co. Inc. (United States) Revenue: by Geography 2022
  • Figure 39. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Mylan N.V. (United States) Revenue: by Geography 2022
  • Figure 41. Novartis International AG (Sandoz) Revenue, Net Income and Gross profit
  • Figure 42. Novartis International AG (Sandoz) Revenue: by Geography 2022
  • Figure 43. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 45. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 46. Sanofi (France) Revenue: by Geography 2022
  • Figure 47. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 48. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2022
  • Figure 49. Global Oral Antibiotics: by Type USD Million (2023-2028)
  • Figure 50. Global Oral Antibiotics: by Application USD Million (2023-2028)
  • Figure 51. Global Oral Antibiotics: by Spectrum of Activity USD Million (2023-2028)
  • Figure 52. Global Oral Antibiotics: by Drug Origin USD Million (2023-2028)
  • Figure 53. Global Oral Antibiotics: by Class USD Million (2023-2028)
  • Figure 54. South America Oral Antibiotics Share (%), by Country
  • Figure 55. Asia Pacific Oral Antibiotics Share (%), by Country
  • Figure 56. Europe Oral Antibiotics Share (%), by Country
  • Figure 57. MEA Oral Antibiotics Share (%), by Country
  • Figure 58. North America Oral Antibiotics Share (%), by Country
  • Figure 59. Global Oral Antibiotics: by Type KG (2023-2028)
  • Figure 60. Global Oral Antibiotics: by Application KG (2023-2028)
  • Figure 61. Global Oral Antibiotics: by Spectrum of Activity KG (2023-2028)
  • Figure 62. Global Oral Antibiotics: by Drug Origin KG (2023-2028)
  • Figure 63. Global Oral Antibiotics: by Class KG (2023-2028)
  • Figure 64. South America Oral Antibiotics Share (%), by Country
  • Figure 65. Asia Pacific Oral Antibiotics Share (%), by Country
  • Figure 66. Europe Oral Antibiotics Share (%), by Country
  • Figure 67. MEA Oral Antibiotics Share (%), by Country
  • Figure 68. North America Oral Antibiotics Share (%), by Country
  • Figure 69. Global Oral Antibiotics: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Allergan Plc. (Ireland)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline plc (United Kingdom)
  • Merck & Co. Inc. (United States)
  • Mylan N.V. (United States)
  • Novartis International AG (Sandoz)
  • Pfizer Inc. (United States)
  • Sanofi (France)
  • Teva Pharmaceutical Industries Ltd. (Israel)
Select User Access Type

Key Highlights of Report


May 2023 242 Pages 82 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Oral Antibiotics Market Quantitative research analysis
Global Oral Antibiotics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Oral Antibiotics market are Abbott Laboratories (United States), Allergan Plc. (Ireland), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc (United Kingdom), Merck & Co. Inc. (United States), Mylan N.V. (United States), Novartis International AG (Sandoz), Pfizer Inc. (United States), Sanofi (France) and Teva Pharmaceutical Industries Ltd. (Israel).
In this highly competitive & fast evolving Oral Antibiotics industry, the top strategic priorities would remain consistent like innovation, R&D, and M&A.
Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract Infections (LRTI)), Urinary Acquired Tract Infections (UTIS), Dental (Combination, and Monotherapies) and Others are the potential customers of Oral Antibiotics industry.

Know More About Global Oral Antibiotics Market Report?

Have a Query? Click Here

Other Related Reports

Peripheral Artery Disease Comprehensive Study by Type (Peripheral Angioplasty Balloons,, Peripheral Stents,, Peripheral Catheters,, Inferior Vena Cava (IVC), Plaque Modification Devices, Hemodynamic ...
$ 3750
Parkinson's Disease Drugs Comprehensive Study by Type (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Route of Administration (Oral, Injection, Transdermal), End-users (Hospitals, C...
$ 3450
Antitumor Antibiotics Comprehensive Study by Type (Anthracyclines (doxorubicin, daunorubicin, epirubicin, mitoxantrone, and idarubicin), Chromomycin (dactinomycin and plicamycin), Miscellaneous (mito...
$ 3650
Tourette Syndrome Treatment Comprehensive Study by Treatment (Medication, Therapy), Distribution Channel (Online, Offline), Medication (Botulinum (Botox) injections, ADHD medications, Central adrener...
$ 3750
Varicella Live Vaccine Comprehensive Study by Type (Single-antigen Vaccine, Combined Vaccine), Application (Chickenpox Immunization, Herpes Zoster Immunization, MMRV Immunization), End-user (Hospital...
$ 3650
Zinc Deficiency Treatment Comprehensive Study by Type (Dietary Supplements, Oral Repletion Therapy), Application (Malnutrition, Anorexia, Oral Ulcers, Acne), Route of Administration (Oral Solids, Sy...
$ 3750